BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 25205401)

  • 21. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A point mutation within exon 5 of the WT1 gene of a sporadic unilateral Wilms' tumor alters gene function.
    Guan LS; Liu JJ; Xu YH; Wang ZY
    Cancer Res; 1998 Sep; 58(18):4180-4. PubMed ID: 9751632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1.
    Cook DM; Hinkes MT; Bernfield M; Rauscher FJ
    Oncogene; 1996 Oct; 13(8):1789-99. PubMed ID: 8895526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
    Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
    Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.
    Nichols KE; Re GG; Yan YX; Garvin AJ; Haber DA
    Cancer Res; 1995 Oct; 55(20):4540-3. PubMed ID: 7553624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
    Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
    Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and analysis of mutations in WTX and WT1 genes in peripheral blood and tumor tissue of children with Wilms' tumor.
    Wang H; Shen Y; Sun N; Jiang YP; Li ML; Sun L
    Chin Med J (Engl); 2012 May; 125(10):1733-9. PubMed ID: 22800892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
    McCoy C; McGee SB; Cornwell MM
    Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the cellular protein encoded by the human Wilms' tumor (WT1) gene.
    Telerman A; Dodemont H; Degraef C; Galand P; Bauwens S; Van Oostveldt P; Amson RB
    Oncogene; 1992 Dec; 7(12):2545-8. PubMed ID: 1334252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis.
    Kijima N; Hosen N; Kagawa N; Hashimoto N; Kinoshita M; Oji Y; Sugiyama H; Yoshimine T
    Anticancer Res; 2014 Jan; 34(1):61-7. PubMed ID: 24403445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice.
    Smith SI; Down M; Boyd AW; Li CL
    Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proto-oncogene N-myc promoter is down regulated by the Wilms' tumor suppressor gene WT1.
    Zhang X; Xing G; Saunders GF
    Anticancer Res; 1999; 19(3A):1641-8. PubMed ID: 10470095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.
    Klattig J; Sierig R; Kruspe D; Besenbeck B; Englert C
    Mol Cell Biol; 2007 Jun; 27(12):4355-64. PubMed ID: 17420277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapeutic targeting of Wilms' tumor protein.
    Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
    Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
    Sugiyama H
    Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physical and functional interaction between the HCMV IE2 protein and the Wilms' tumor suppressor WT1.
    Kim JM; Hong Y; Semba K; Kim S
    Biochem Biophys Res Commun; 2000 Jan; 267(1):59-63. PubMed ID: 10623574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1).
    Adachi Y; Matsubara S; Pedraza C; Ozawa M; Tsutsui J; Takamatsu H; Noguchi H; Akiyama T; Muramatsu T
    Oncogene; 1996 Nov; 13(10):2197-203. PubMed ID: 8950987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
    Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
    Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
    Wagner KJ; Roberts SG
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.